Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak.

Kuan JW, Su AT, Tay SP, Fong IL, Kubota S, Su'ut L, Osato M, Sashida G.

Int J Hematol. 2019 Nov 9. doi: 10.1007/s12185-019-02768-x. [Epub ahead of print]

PMID:
31707540
2.

Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.

Hayashi Y, Goyama S, Liu X, Tamura M, Asada S, Tanaka Y, Fukuyama T, Wunderlich M, O'Brien E, Mizukawa B, Yamazaki S, Matsumoto A, Yamasaki S, Shibata T, Matsuda K, Sashida G, Takizawa H, Kitamura T.

Nat Commun. 2019 Oct 25;10(1):4869. doi: 10.1038/s41467-019-12555-1.

3.

Author Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

Nat Commun. 2019 Aug 28;10(1):3943. doi: 10.1038/s41467-019-11919-x.

4.

Systematic Review of Normal Subjects Harbouring BCR-ABL1 Fusion Gene.

Kuan JW, Su AT, Leong CF, Osato M, Sashida G.

Acta Haematol. 2019 Aug 9:1-16. doi: 10.1159/000501146. [Epub ahead of print]

PMID:
31401626
5.

Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.

Tenjin Y, Kudoh S, Kubota S, Yamada T, Matsuo A, Sato Y, Ichimura T, Kohrogi H, Sashida G, Sakagami T, Ito T.

Lab Invest. 2019 Nov;99(11):1622-1635. doi: 10.1038/s41374-019-0277-y. Epub 2019 Jun 23.

PMID:
31231131
6.

RUNX3 levels in human hematopoietic progenitors are regulated by aging and dictate erythroid-myeloid balance.

Balogh P, Adelman ER, Pluvinage JV, Capaldo BJ, Freeman KC, Singh S, Elagib KE, Nakamura Y, Kurita R, Sashida G, Zunder ER, Li H, Gru AA, Price EA, Schrier SL, Weissman IL, Figueroa ME, Pang WW, Goldfarb AN.

Haematologica. 2019 Jun 6. pii: haematol.2018.208918. doi: 10.3324/haematol.2018.208918. [Epub ahead of print]

7.

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

Nat Commun. 2019 Apr 10;10(1):1653. doi: 10.1038/s41467-019-09710-z. Erratum in: Nat Commun. 2019 Aug 28;10(1):3943.

8.

Deregulated Polycomb functions in myeloproliferative neoplasms.

Sashida G, Oshima M, Iwama A.

Int J Hematol. 2019 Aug;110(2):170-178. doi: 10.1007/s12185-019-02600-6. Epub 2019 Jan 31. Review.

PMID:
30706327
9.

Correction to: Systematic review of pre-clinical chronic myeloid leukaemia.

Kuan JW, Su AT, Leong CF, Osato M, Sashida G.

Int J Hematol. 2019 Jan;109(1):130. doi: 10.1007/s12185-018-2556-6.

PMID:
30406326
10.

Ezh1 Targets Bivalent Genes to Maintain Self-Renewing Stem Cells in Ezh2-Insufficient Myelodysplastic Syndrome.

Aoyama K, Oshima M, Koide S, Suzuki E, Mochizuki-Kashio M, Kato Y, Tara S, Shinoda D, Hiura N, Nakajima-Takagi Y, Sashida G, Iwama A.

iScience. 2018 Nov 30;9:161-174. doi: 10.1016/j.isci.2018.10.008. Epub 2018 Oct 15.

11.

Systematic review of pre-clinical chronic myeloid leukaemia.

Kuan JW, Su AT, Leong CF, Osato M, Sashida G.

Int J Hematol. 2018 Nov;108(5):465-484. doi: 10.1007/s12185-018-2528-x. Epub 2018 Sep 14. Review. Erratum in: Int J Hematol. 2018 Nov 7;:.

PMID:
30218276
12.

Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes.

Hayashi Y, Zhang Y, Yokota A, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, Zhou Y, Wang J, Wu L, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale LE, Harada H, Shih LY, Tse W, Bridges JP, Caligiuri MA, Huang T, Zheng Y, Witte DP, Wang QF, Qu CK, Salomonis N, Grimes HL, Nimer SD, Xiao Z, Huang G.

Cancer Discov. 2018 Nov;8(11):1438-1457. doi: 10.1158/2159-8290.CD-17-1203. Epub 2018 Aug 23.

13.

Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.

Wang C, Oshima M, Sato D, Matsui H, Kubota S, Aoyama K, Nakajima-Takagi Y, Koide S, Matsubayashi J, Mochizuki-Kashio M, Nakano-Yokomizo T, Bai J, Nagao T, Kanai A, Iwama A, Sashida G.

J Clin Invest. 2018 Aug 31;128(9):3872-3886. doi: 10.1172/JCI94645. Epub 2018 Aug 6.

14.

Epigenetic dysregulation in myelodysplastic syndromes.

Sashida G.

Rinsho Ketsueki. 2017;58(10):1809-1817. doi: 10.11406/rinketsu.58.1809. Japanese.

PMID:
28978819
15.

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.

Sashida G, Iwama A.

Int J Hematol. 2017 Jan;105(1):23-30. doi: 10.1007/s12185-016-2124-x. Epub 2016 Nov 9. Review.

PMID:
27830540
16.

Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.

Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A.

Leukemia. 2017 Apr;31(4):861-871. doi: 10.1038/leu.2016.268. Epub 2016 Oct 3.

PMID:
27694924
17.

The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition.

Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, Mochizuki-Kashio M, Harada H, Shimoda K, Iwama A.

J Exp Med. 2016 Jul 25;213(8):1459-77. doi: 10.1084/jem.20151121. Epub 2016 Jul 11.

18.

Leukemia Inhibitory Factor Enhances Endogenous Cardiomyocyte Regeneration after Myocardial Infarction.

Kanda M, Nagai T, Takahashi T, Liu ML, Kondou N, Naito AT, Akazawa H, Sashida G, Iwama A, Komuro I, Kobayashi Y.

PLoS One. 2016 May 26;11(5):e0156562. doi: 10.1371/journal.pone.0156562. eCollection 2016.

19.

[Mutations of epigenetic regulator genes and myeloid malignancies].

Muto T, Sashida G, Oshima M, Iwama A.

Rinsho Ketsueki. 2015 Nov;56(11):2287-94. doi: 10.11406/rinketsu.56.2287. Japanese.

PMID:
26666714
20.

Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms.

Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Hidaka T, Kubuki Y, Sashida G, Aoyama K, Yoshimitsu M, Abe H, Miike T, Iwakiri H, Tahara Y, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K.

Genom Data. 2015 Apr 9;4:102-8. doi: 10.1016/j.gdata.2015.04.002. eCollection 2015 Jun.

21.

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.

Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, Wang C, Iwama A.

Blood. 2015 Sep 3;126(10):1172-83. doi: 10.1182/blood-2015-03-634428. Epub 2015 Jul 28.

PMID:
26219303
22.

Non-Lethal Ionizing Radiation Promotes Aging-Like Phenotypic Changes of Human Hematopoietic Stem and Progenitor Cells in Humanized Mice.

Wang C, Oshima M, Sashida G, Tomioka T, Hasegawa N, Mochizuki-Kashio M, Nakajima-Takagi Y, Kusunoki Y, Kyoizumi S, Imai K, Nakachi K, Iwama A.

PLoS One. 2015 Jul 10;10(7):e0132041. doi: 10.1371/journal.pone.0132041. eCollection 2015.

23.

[Epigenetic dysregulation in myelodysplastic syndrome].

Sashida G, Iwama A.

Rinsho Ketsueki. 2015 Feb;56(2):111-8. doi: 10.11406/rinketsu.56.111. Review. Japanese.

PMID:
25765789
24.

Histone acetylation mediated by Brd1 is crucial for Cd8 gene activation during early thymocyte development.

Mishima Y, Wang C, Miyagi S, Saraya A, Hosokawa H, Mochizuki-Kashio M, Nakajima-Takagi Y, Koide S, Negishi M, Sashida G, Naito T, Ishikura T, Onodera A, Nakayama T, Tenen DG, Yamaguchi N, Koseki H, Taniuchi I, Iwama A.

Nat Commun. 2014 Dec 18;5:5872. doi: 10.1038/ncomms6872.

25.

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.

Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K.

Blood. 2015 Jan 8;125(2):304-15. doi: 10.1182/blood-2014-04-555508. Epub 2014 Nov 13.

PMID:
25395421
26.

Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.

Sashida G, Harada H, Matsui H, Oshima M, Yui M, Harada Y, Tanaka S, Mochizuki-Kashio M, Wang C, Saraya A, Muto T, Hayashi Y, Suzuki K, Nakajima H, Inaba T, Koseki H, Huang G, Kitamura T, Iwama A.

Nat Commun. 2014 Jun 23;5:4177. doi: 10.1038/ncomms5177.

PMID:
24953053
27.

Myelodysplastic syndrome with extramedullary erythroid hyperplasia induced by loss of Tet2 in mice.

Muto T, Sashida G, Hasegawa N, Nakaseko C, Yokote K, Shimoda K, Iwama A.

Leuk Lymphoma. 2015 Feb;56(2):520-3. doi: 10.3109/10428194.2014.924120. Epub 2014 Jul 17. No abstract available.

PMID:
24844363
28.

Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia.

Wang C, Sashida G, Saraya A, Ishiga R, Koide S, Oshima M, Isono K, Koseki H, Iwama A.

Blood. 2014 May 22;123(21):3336-43. doi: 10.1182/blood-2013-12-544544. Epub 2014 Apr 15.

PMID:
24735968
29.

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.

Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A.

J Exp Med. 2013 Nov 18;210(12):2627-39. doi: 10.1084/jem.20131144. Epub 2013 Nov 11.

30.

RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes.

Harada Y, Inoue D, Ding Y, Imagawa J, Doki N, Matsui H, Yahata T, Matsushita H, Ando K, Sashida G, Iwama A, Kitamura T, Harada H.

Blood. 2013 Apr 25;121(17):3434-46. doi: 10.1182/blood-2012-06-434423. Epub 2013 Mar 7.

PMID:
23471304
31.

Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.

Liu Y, Liu F, Yu H, Zhao X, Sashida G, Deblasio A, Harr M, She QB, Chen Z, Lin HK, Di Giandomenico S, Elf SE, Yang Y, Miyata Y, Huang G, Menendez S, Mellinghoff IK, Rosen N, Pandolfi PP, Hedvat CV, Nimer SD.

Sci Signal. 2012 Oct 23;5(247):ra77. doi: 10.1126/scisignal.2003199.

32.

Epigenetic regulation of hematopoiesis.

Sashida G, Iwama A.

Int J Hematol. 2012 Oct;96(4):405-12. doi: 10.1007/s12185-012-1183-x. Epub 2012 Sep 29. Review.

PMID:
23054647
33.

Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.

Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, Grimes HL, Caligiuri MA, Huang G.

Blood. 2012 Aug 2;120(5):1118-29. doi: 10.1182/blood-2012-02-412379. Epub 2012 Jun 26.

34.

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.

Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, Koseki H, Iwama A.

Blood. 2012 Aug 2;120(5):1107-17. doi: 10.1182/blood-2011-11-394932. Epub 2012 Jun 7.

PMID:
22677129
35.

The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.

Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, Yang Y, Yan X, Zhang P, Tenen DG, Osato M, Hsieh JJ, Nimer SD.

Blood. 2011 Dec 15;118(25):6544-52. doi: 10.1182/blood-2010-11-317909. Epub 2011 Oct 19.

36.

The mef/elf4 transcription factor fine tunes the DNA damage response.

Sashida G, Bae N, Di Giandomenico S, Asai T, Gurvich N, Bazzoli E, Liu Y, Huang G, Zhao X, Menendez S, Nimer SD.

Cancer Res. 2011 Jul 15;71(14):4857-65. doi: 10.1158/0008-5472.CAN-11-0455. Epub 2011 May 26.

37.

The oncogenic role of the ETS transcription factors MEF and ERG.

Sashida G, Bazzoli E, Menendez S, Liu Y, Nimer SD.

Cell Cycle. 2010 Sep 1;9(17):3457-9. Epub 2010 Sep 13. Review.

38.

Cyclin C regulates human hematopoietic stem/progenitor cell quiescence.

Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, Naoe T, Moore M, Nimer SD.

Stem Cells. 2010 Feb;28(2):308-17. doi: 10.1002/stem.270.

39.

The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior.

Liu Y, Elf SE, Asai T, Miyata Y, Liu Y, Sashida G, Huang G, Di Giandomenico S, Koff A, Nimer SD.

Cell Cycle. 2009 Oct 1;8(19):3120-4. Review.

40.

ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation.

Sashida G, Liu Y, Elf S, Miyata Y, Ohyashiki K, Izumi M, Menendez S, Nimer SD.

Mol Cell Biol. 2009 Jul;29(13):3687-99. doi: 10.1128/MCB.01551-08. Epub 2009 Apr 20.

41.

p53 regulates hematopoietic stem cell quiescence.

Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, Antipin J, Reva B, Koff A, Nimer SD.

Cell Stem Cell. 2009 Jan 9;4(1):37-48. doi: 10.1016/j.stem.2008.11.006.

42.

Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.

Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, Broxmeyer HE, Ohyashiki JH, Ohyashiki K.

Stem Cells Dev. 2007 Jun;16(3):503-14.

PMID:
17610380
43.

Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.

Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, Sashida G, Ohyashiki JH, Ohyashiki K.

Oncogene. 2007 Jun 14;26(28):4179-88. Epub 2007 Jan 8.

PMID:
17213809
44.

Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.

Liu YC, Ito Y, Hsiao HH, Sashida G, Kodama A, Ohyashiki JH, Ohyashiki K.

Cancer Genet Cytogenet. 2006 Nov;171(1):9-16.

PMID:
17074585
45.

[Effectiveness of long term administration of humanized anti-interleukin-6 receptor antibody (tocilizumab) for multicentric Castleman's disease with pulmonary involvement].

Akahane D, Kimura Y, Sumi M, Sashida G, Gotoh A, Miyazawa K, Ohyashiki K.

Rinsho Ketsueki. 2006 Aug;47(8):748-52. Japanese.

PMID:
16986713
46.

Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly.

Liu YC, Miyazawa K, Sashida G, Kodama A, Ohyashiki K.

Cancer Genet Cytogenet. 2006 Aug;169(1):69-72.

PMID:
16875940
47.

Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome.

Ishii Y, Hsiao HH, Sashida G, Ito Y, Miyazawa K, Kodama A, Ohyashiki JH, Ohyashiki K.

Cancer Genet Cytogenet. 2006 Jun;167(2):131-7.

PMID:
16737912
48.

Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia.

Tauchi T, Shin-ya K, Sashida G, Sumi M, Okabe S, Ohyashiki JH, Ohyashiki K.

Oncogene. 2006 Sep 21;25(42):5719-25. Epub 2006 May 1.

PMID:
16652154
49.

Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10).

Hsiao HH, Sashida G, Ito Y, Kodama A, Fukutake K, Ohyashiki JH, Ohyashiki K.

Cancer Genet Cytogenet. 2006 Mar;165(2):161-6.

PMID:
16527611
50.

Translocation (4;9)(q11;q33), a new rearrangement in acute myeloid leukemia with central nervous system involvement.

Liu YC, Sashida G, Kodama A, Ohyashiki K.

Cancer Genet Cytogenet. 2006 Feb;165(1):85-6. No abstract available.

PMID:
16490604

Supplemental Content

Loading ...
Support Center